EX-10.1



 Exhibit 10.1 

AMENDMENT NO. 1 TO SALES AGREEMENT 

August 25, 2015 
 Cowen and Company, LLC 

599 Lexington Avenue 
 New York, NY 10022 

Ladies and Gentlemen: 
 EnteroMedics
Inc., a Delaware corporation (the “Company”), and Cowen and Company, LLC (“Cowen”), are parties to that certain Sales Agreement dated June 13, 2014 (the “Original Agreement”). All
capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement. The parties, intending to be legally bound, hereby amend the Original Agreement as follows: 

1. Section 1 of the Original Agreement is hereby deleted and replaced with the following: 

“Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agreement, on the
terms and subject to the conditions set forth herein, it may issue and sell through Cowen, acting as agent and/or principal, shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) having an
aggregate offering price of up to $25,000,000 by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act (as defined below). Notwithstanding anything to the contrary contained
herein, the parties hereto agree that compliance with the limitation set forth in this Section 1 on the number of shares of Common Stock issued and sold under this Agreement shall be the sole responsibility of the Company, and Cowen shall have
no obligation in connection with such compliance. Pursuant to this Agreement, shares of our common stock were previously sold for $7,579,013 in aggregate gross proceeds under a separate prospectus supplement. Under this Agreement, as amended by
Amendment No. 1 to Sales Agreement, the Company, through Cowen, may offer and sell further shares of common stock having an aggregate offering price of up to $17,420,987 pursuant to the Prospectus (as defined below). The issuance and sale of
Common Stock through Cowen will be effected pursuant to the Registration Statement (as defined below) filed by the Company and declared effective by the Securities and Exchange Commission (the “Commission”), although nothing
in this Agreement shall be construed as requiring the Company to use the Registration Statement (as defined below) to issue the Common Stock. 

The Company has filed, in accordance with the provisions of the Securities Act of 1933, as amended, and the rules and
regulations thereunder (collectively, the “Securities Act”), with the Commission a registration statement on Form S-3 (File No. 333- 195855), including a base prospectus, relating to certain securities, including the
Common Stock, to be issued from time to time by the Company, and which incorporates by reference documents that the Company has filed or will file in accordance with the provisions of the 







 
Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (collectively, the “Exchange Act”). The Company has prepared a prospectus supplement
specifically relating to the Common Stock being offered under this Agreement (the “Prospectus Supplement”) to the base prospectus included as part of such registration statement. The Company has furnished to Cowen, for use by
Cowen, copies of the prospectus included as part of such registration statement, as supplemented by the Prospectus Supplement, relating to the Common Stock. Except where the context otherwise requires, such registration statement, as amended when it
became effective, including all documents filed as part thereof or incorporated by reference therein, and including any information contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the
Securities Act or deemed to be a part of such registration statement pursuant to Rule 430B or 462(b) of the Securities Act, is herein called the “Registration Statement.” The base prospectus, including all documents
incorporated therein by reference, included in the Registration Statement, as it may be supplemented by the Prospectus Supplement, in the form in which such prospectus and/or Prospectus Supplement have most recently been filed by the Company with
the Commission pursuant to Rule 424(b) under the Securities Act, together with any “issuer free writing prospectus,” as defined in Rule 433 of the Securities Act Regulations (“Rule 433”), relating to the Common Stock offered
under this Agreement that (i) is required to be filed with the Commission by the Company or (ii) is exempt from filing pursuant to Rule 433(d)(5)(i), in each case in the form filed or required to be filed with the Commission or, if not
required to be filed, in the form retained in the Company’s records pursuant to Rule 433(g), is herein called the “Prospectus.” Any reference herein to the Registration Statement, the Prospectus or any amendment or
supplement thereto shall be deemed to refer to and include the documents incorporated by reference therein, and any reference herein to the terms “amend,” “amendment” or “supplement” with respect to the Registration
Statement or the Prospectus shall be deemed to refer to and include the filing after the execution hereof of any document with the Commission deemed to be incorporated by reference therein. For purposes of this Agreement, all references to the
Registration Statement, the Prospectus or to any amendment or supplement thereto shall be deemed to include any copy filed with the Commission pursuant to either the Electronic Data Gathering Analysis and Retrieval System or Interactive Data
Electronic Applications (collectively “IDEA”). 
 2. In Section 6 of the Original Agreement, clause (gg) is
deleted and replaced with the words “Intentionally omitted.” 
 3. All references to “June 13, 2014” set forth in
Schedule 1 and Exhibit 7(l) of the Original Agreement are revised to read “June 13, 2014 (as amended by Amendment No. 1 to Sales Agreement, dated August 25, 2015)”. 

4. Except as specifically set forth herein, all other provisions of the Original Agreement shall remain in full force and effect. 

5. Entire Agreement; Amendment; Severability. This Amendment No. 1 together with the Original Agreement (including all schedules
and exhibits attached hereto and thereto 

  
 2 








 
and Placement Notices issued pursuant hereto and thereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings, both written and oral,
among the parties hereto with regard to the subject matter hereof. All references in the Original Agreement to the “Agreement” shall mean the Original Agreement as amended by this Amendment No. 1; provided, however, that all
references to “date of this Agreement” in the Original Agreement shall continue to refer to the date of the Original Agreement, and the reference to “time of execution of this Agreement” set forth in Section 13(a) shall
continue to refer to the time of execution of the Original Agreement. 
 6. Applicable Law; Consent to Jurisdiction. This amendment
shall be governed by, and construed in accordance with, the internal laws of the State of New York without regard to the principles of conflicts of laws. Each party hereby irrevocably submits to the non-exclusive jurisdiction of the state and
federal courts sitting in the City of New York, borough of Manhattan, for the adjudication of any dispute hereunder or in connection with any transaction contemplated hereby, and hereby irrevocably waives, and agrees not to assert in any suit,
action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each
party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof (certified or registered mail, return receipt requested) to such party at the address
in effect for notices to it under this amendment and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
manner permitted by law. 
 7. Waiver of Jury Trial. The Company and Cowen each hereby irrevocably waives any right it may have to a
trial by jury in respect of any claim based upon or arising out of this amendment or any transaction contemplated hereby. 
 8.
Counterparts. This amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed amendment by one party to the
other may be made by facsimile transmission. 
 [Remainder of Page Intentionally Blank] 

  
 3 








 If the foregoing correctly sets forth the understanding among the Company and Cowen, please so
indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding amendment to the Agreement between the Company and Cowen. 

 

			
	Very truly yours,
	
	ENTEROMEDICS INC.
		
	By:	 	 /s/ Greg S. Lea

	Name:	 	Greg S. Lea
	Title:	 	Chief Financial Officer and Chief Operating Officer
	
	ACCEPTED as of the date first-above written:
	
	COWEN AND COMPANY, LLC
		
	By:	 	 /s/ Kevin J. Raidy

	Name:	 	Kevin J. Raidy
	Title:	 	Managing Director